CSL Stock Overview Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for CSL Historical stock prices Current Share Price AU$258.89 52 Week High AU$313.55 52 Week Low AU$253.04 Beta 0.32 1 Month Change -5.31% 3 Month Change -6.36% 1 Year Change -9.17% 3 Year Change -2.23% 5 Year Change -18.46% Change since IPO 32,261.57%
Recent News & Updates
CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine Feb 15
European Commission Approves CSL's ANDEMBRY®? (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) Feb 14
First half dividend of US$1.30 announced Feb 13
First half 2025 earnings: EPS and revenues miss analyst expectations Feb 12 Joy Linton Resumes the Role of Chief Financial Officer of CSL Limited
CSL Behring's Gene Therapy HEMGENIX®? (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B Feb 08 See more updates
CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine Feb 15
European Commission Approves CSL's ANDEMBRY®? (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) Feb 14
First half dividend of US$1.30 announced Feb 13
First half 2025 earnings: EPS and revenues miss analyst expectations Feb 12 Joy Linton Resumes the Role of Chief Financial Officer of CSL Limited
CSL Behring's Gene Therapy HEMGENIX®? (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B Feb 08
Should You Be Adding CSL (ASX:CSL) To Your Watchlist Today? Jan 31
CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 43% Above Its Share Price Jan 10
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE) Dec 14
MD, CEO & Executive Director recently sold AU$1.1m worth of stock Nov 07
With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case Nov 01
CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy Oct 17
We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt Oct 05
CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances Sep 18
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain Sep 14
MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock Sep 07
Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely Sep 03
Upcoming dividend of US$1.45 per share Sep 02
CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? Aug 16
Final dividend of US$1.45 announced Aug 15
Full year 2024 earnings: EPS misses analyst expectations Aug 13 CSL Limited to Report First Half, 2025 Results on Feb 11, 2025
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued Aug 07
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine May 23
CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings May 22
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued May 01
Now 21% undervalued after recent price drop Apr 27
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy Apr 24
Does CSL (ASX:CSL) Have A Healthy Balance Sheet? Mar 19
Now 20% undervalued Mar 11
CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee Mar 06
Upcoming dividend of US$1.19 per share Mar 04
First half dividend of US$1.19 announced Feb 16
First half 2024 earnings: EPS misses analyst expectations Feb 14 CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024
CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human) Feb 12
Now 22% undervalued Feb 12
Now 21% undervalued Jan 16
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster Dec 21
CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024 Dec 15
CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B Dec 12
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults Nov 29
Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B Oct 28
CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024 Oct 17 CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources Sep 20
Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19 Sep 06
Upcoming dividend of US$1.29 per share at 1.4% yield Sep 04
Independent Non-Executive Chairman recently sold AU$5.6m worth of stock Aug 26
CSL Appoints Jeffrey Ball as First Chief Sustainability Officer Aug 18 CSL Limited, Annual General Meeting, Oct 09, 2024
Full year 2023 earnings: EPS misses analyst expectations Aug 15
CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023 Aug 04
Upcoming dividend of US$1.07 per share at 1.1% yield Mar 02
First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022) Feb 14
CSL Limited Announces Interim Dividend, Payable on 5 April 2023 Feb 14
CSL Limited, Annual General Meeting, Oct 11, 2023 Jan 10
CSL Limited to Report First Half, 2023 Results on Feb 14, 2023 Jan 09 SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases Jan 06
CSL Limited Announces Management Changes CSL Limited Announces Chief Executive Officer Changes
CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B Nov 23
Independent Non Executive Director recently bought AU$74k worth of stock Oct 22
Consensus forecasts updated Oct 19
Now 20% undervalued Oct 07
CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates Oct 06
Now 20% undervalued Sep 14
MD, CEO & Executive Director exercised options and sold AU$4.7m worth of stock Sep 03
Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock Sep 03
Upcoming dividend of US$1.18 per share Aug 30
Non-Independent Non-Executive Director exercised options to buy AU$11m worth of stock. Aug 27
CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE) Aug 18
Full year 2022 earnings: EPS in line with expectations, revenues disappoint Aug 18 CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022
Now 20% undervalued Aug 12 Shareholder Returns CSL AU Biotechs AU Market 7D 1.9% 2.2% -0.2% 1Y -9.2% -0.2% 8.9%
See full shareholder returns
Return vs Market: CSL underperformed the Australian Market which returned 8.9% over the past year.
Price Volatility Is CSL's price volatile compared to industry and market? CSL volatility CSL Average Weekly Movement 2.4% Biotechs Industry Average Movement 9.4% Market Average Movement 7.9% 10% most volatile stocks in AU Market 16.4% 10% least volatile stocks in AU Market 3.1%
Stable Share Price: CSL has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CSL's weekly volatility (2%) has been stable over the past year.
About the Company CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Show more CSL Limited Fundamentals Summary How do CSL's earnings and revenue compare to its market cap? CSL fundamental statistics Market cap AU$128.24b Earnings (TTM ) AU$4.33b Revenue (TTM ) AU$23.99b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CSL income statement (TTM ) Revenue US$15.23b Cost of Revenue US$7.31b Gross Profit US$7.92b Other Expenses US$5.18b Earnings US$2.75b
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 19, 2025
Earnings per share (EPS) 5.68 Gross Margin 52.02% Net Profit Margin 18.04% Debt/Equity Ratio 50.4%
How did CSL perform over the long term?
See historical performance and comparison Dividends
1.6% Current Dividend Yield When do you need to buy CSL by to receive an upcoming dividend? CSL dividend dates Ex Dividend Date Mar 10 2025 Dividend Pay Date Apr 09 2025 Days until Ex dividend 17 days Days until Dividend pay date 47 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/20 14:27 End of Day Share Price 2025/02/20 00:00 Earnings 2024/12/31 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources CSL Limited is covered by 28 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Saul Hadassin Barrenjoey Markets Pty Limited Thomas Wakim Bell Potter Lyanne Harrison BofA Global Research
Show 25 more analysts 
